Browsing by Subject "Prostate cancer"
Now showing items 1-7 of 7
-
Bortezomib represses HIF-1 alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells
(2012)Bortezomib represents the first proteasome inhibitor (PI) with demonstrated antitumor activity in the clinical setting, particularly for treatment of hematological malignancies. At the preclinical level, its action is shown ... -
CD10 Is Inversely Associated with Nuclear Factor-Kappa B and Predicts Biochemical Recurrence after Radical Prostatectomy
(2012)Introduction: The cell surface endopeptidase CD10 (neutral endopeptidase) and nuclear factor-kappa B (NF-kappa B) have been independently associated with prostate cancer (PC) progression. We investigated the correlations ... -
Development of a New Optical Device and Its Feasibility in Prostate Cancer Detection
(2012)Aim: To develop a new optical device (prostate optical device, POD) for assessment of prostate tissue stiffness and evaluate its sensitivity and specificity in prostate cancer detection. Patients and Methods: POD was tested ... -
The effects of obesity and diet on prostate cancer risk
(2003)Prostate cancer is nowadays the most common malignancy in males of the western world, but little is as yet known regarding the causes of initiation and progression of this disease. To explain the geographical variations ... -
Genetic polymorphisms in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and prostate cancer risk in Caucasian men
(2010)Background: Catechol-estrogen metabolites can induce carcinogenesis by acting as endogenous tumor initiators. Glucuronidation, mediated by the UDP-glucuronosyltransferase 1A1 (UGT1A1) enzyme, is a main metabolic pathway ... -
Prostate cancer: ESMO consensus conference guidelines 2012
(2013)The first ESMO Consensus Conference on prostate cancer was held in Zurich, Switzerland, on 17-19 November 2011, with the participation of a multidisciplinary panel of leading professionals including experts in methodological ... -
Treatment of Low-risk Prostate Cancer with Radical Hypofractionated Accelerated Radiotherapy with Cytoprotection (HypoARC): An Interim Analysis of Toxicity and Efficacy
(2011)Aim: Radiobiological analysis of clinical data suggests that prostate cancer has a low alpha/beta ratio, implying that large radiotherapy fractions may better control the disease. Acceleration of radiotherapy may be also ...